Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CLSD

CLSD - Clearside Biomedical Inc Stock Price, Fair Value and News

$0.87-0.03 (-3.33%)
Market Closed

1/100

CLSD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

1/100

CLSD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.87

Target 3M

$0.98

Target 6M

$0.93

CLSD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLSD Price Action

Last 7 days

4.6%

Last 30 days

44.3%

Last 90 days

-70.8%

Trailing 12 Months

-91.8%

CLSD RSI Chart

CLSD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLSD Valuation

Market Cap

4.6M

Price/Earnings (Trailing)

-0.18

Price/Sales (Trailing)

1.37

EV/EBITDA

0.09

Price/Free Cashflow

-0.21

CLSD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.87

Target 3M

$0.98

Target 6M

$0.93

CLSD Fundamentals

CLSD Revenue

Revenue (TTM)

3.3M

Rev. Growth (Yr)

-80.64%

Rev. Growth (Qtr)

-59.15%

CLSD Earnings

Earnings (TTM)

-26.0M

Earnings Growth (Yr)

22.32%

Earnings Growth (Qtr)

-32.86%

CLSD Profitability

EBT Margin

-770.89%

Return on Equity

48.19%

Return on Assets

-223.31%

Free Cashflow Yield

-477.56%

CLSD Investor Care

Shares Dilution (1Y)

3.52%

Diluted EPS (TTM)

-5.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.8M4.2M3.3M0
20248.5M7.5M7.7M1.7M
202302.0M2.5M8.6M
202222.5M15.5M8.4M1.3M
202113.3M18.7M24.2M29.6M
20206.2M6.5M9.8M7.9M
2019565.8K1.1M1.6M2.2M
201800030.0K
2017476.3K432.5K388.8K345.0K
2016000520.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Clearside Biomedical Inc

CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEhttps://clearsidebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES36

Clearside Biomedical Inc Frequently Asked Questions

CLSD is the stock ticker symbol of Clearside Biomedical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Clearside Biomedical Inc is 4.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CLSD's fair value in chart for subscribers.

The fair value guage provides a quick view whether CLSD is over valued or under valued. Whether Clearside Biomedical Inc is cheap or expensive depends on the assumptions which impact Clearside Biomedical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLSD.

As of Tue Jan 27 2026, CLSD's PE ratio (Price to Earnings) is -0.18 and Price to Sales (PS) ratio is 1.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLSD PE ratio will change depending on the future growth rate expectations of investors.